KINNATE BIOPHARMA INC's ticker is KNTE and the CUSIP is 49705R105. A total of 72 filers reported holding KINNATE BIOPHARMA INC in Q1 2023. The put-call ratio across all filers is 0.27 and the average weighting 1.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $188 | -48.8% | 134 | +10.7% | 0.00% | – |
Q2 2023 | $367 | -98.8% | 121 | -97.6% | 0.00% | – |
Q1 2023 | $31,894 | +1631.5% | 5,103 | +1589.7% | 0.00% | – |
Q4 2022 | $1,842 | -54.0% | 302 | +6.0% | 0.00% | – |
Q2 2022 | $4,000 | -71.4% | 285 | -76.5% | 0.00% | – |
Q1 2022 | $14,000 | -93.4% | 1,211 | -89.8% | 0.00% | – |
Q4 2021 | $211,000 | +21000.0% | 11,926 | +25826.1% | 0.00% | – |
Q3 2021 | $1,000 | -66.7% | 46 | -66.9% | 0.00% | – |
Q2 2021 | $3,000 | -97.7% | 139 | -96.7% | 0.00% | – |
Q1 2021 | $131,000 | – | 4,216 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Foresite Capital Management IV, LLC | 9,671,643 | $384,738,000 | 41.79% |
Foresite Capital Management V, LLC | 875,001 | $34,808,000 | 25.78% |
Vida Ventures Advisors, LLC | 2,747,074 | $109,279,000 | 22.43% |
VR Adviser, LLC | 1,473,014 | $58,596,000 | 8.62% |
RA Capital Management | 3,593,052 | $142,932,000 | 2.00% |
Logos Global Management LP | 569,602 | $22,659,000 | 1.94% |
Boxer Capital, LLC | 1,064,665 | $42,352,000 | 1.36% |
Orbimed Advisors | 3,847,929 | $153,071,000 | 1.34% |
HARVARD MANAGEMENT CO INC | 498,001 | $19,810,000 | 1.07% |
DAFNA Capital Management LLC | 68,121 | $2,710,000 | 0.81% |